Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
Zhou Q, Meng X, Sun L, Huang D, Yang N, Yu Y, Zhao M, Zhuang W, Guo R, Hu Y, Pan Y, Shan J, Sun M, Yuan Y, Fan Y, Huang J, Liu L, Chu Q, Wang X, Xu C, Lin J, Huang J, Huang M, Sun J, Zhang S, Zhou H, Wu YL. Zhou Q, et al. Among authors: wu yl. J Thorac Oncol. 2024 Dec;19(12):1630-1639. doi: 10.1016/j.jtho.2024.08.005. Epub 2024 Aug 9. J Thorac Oncol. 2024. PMID: 39127176 Clinical Trial.
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Dong S, Wang Z, Zhang JT, Yan B, Zhang C, Gao X, Sun H, Li YS, Yan HH, Tu HY, Liu SM, Gong Y, Gao W, Huang J, Liao RQ, Lin JT, Ke EE, Xu Z, Zhang X, Xia X, Li AN, Liu SY, Pan Y, Yang JJ, Zhong WZ, Yi X, Zhou Q, Yang XN, Wu YL. Dong S, et al. Among authors: wu yl. JAMA Oncol. 2024 Jul 1;10(7):932-940. doi: 10.1001/jamaoncol.2024.1779. JAMA Oncol. 2024. PMID: 38869865 Clinical Trial.
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.
Zhou Q, Li J, Cang SD, Lin JX, Tu HY, Du Y, Qin JW, Liang XH, Yu Y, Lan HT, Shi HQ, Hua D, Liu SM, Wu YL. Zhou Q, et al. Among authors: wu yl. Clin Lung Cancer. 2024 Sep 20:S1525-7304(24)00199-2. doi: 10.1016/j.cllc.2024.09.002. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39424513 Free article.
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
Lu S, Wu L, Wang Q, Wang Z, Lv D, Ma R, Zhu B, van Tran N, Jiang L, Nan K, Laktionov K, Clarke S, Song M, Mann H, Liu Y, Shi X, Wu YL. Lu S, et al. Among authors: wu yl, wu l. J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02433-X. doi: 10.1016/j.jtho.2024.10.024. Online ahead of print. J Thorac Oncol. 2024. PMID: 39521433
Consensus on the lung cancer management after third-generation EGFR-TKI resistance.
Zhou Q, Zhao H, Lu S, Cheng Y, Liu Y, Zhao M, Yu Z, Hu C, Zhang L, Yang F, Zhao J, Guo R, Ma R, Du Y, Dong X, Cui J, Tan DSW, Ahn MJ, Tsuboi M, Maggie Liu SY, Mok TS, Wu YL. Zhou Q, et al. Among authors: wu yl. Lancet Reg Health West Pac. 2024 Dec 11;53:101260. doi: 10.1016/j.lanwpc.2024.101260. eCollection 2024 Dec. Lancet Reg Health West Pac. 2024. PMID: 39759798 Free PMC article. Review.
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection.
Dong S, Yan B, Liu SY, Gao X, Hong HZ, Li HJ, Gao W, Yan HH, Maggie Liu SY, Tu HY, Pan Y, Zhou Q, Yang XN, Xia XF, Yi X, Zhong WZ, Wu YL, Zhang JT. Dong S, et al. Among authors: wu yl. JTO Clin Res Rep. 2024 Nov 2;6(1):100758. doi: 10.1016/j.jtocrr.2024.100758. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39758595 Free PMC article.
2,376 results